TY - JOUR
TI - Selective serotonin re-uptake inhibitors for the treatment of depression in coronary artery disease and chronic heart failure: Evidence for pleiotropic effects
AU - Paraskevaidis, I.
AU - Parissis, J.T.
AU - Fountoulaki, K.
AU - Filippatos, G.
AU - Kremastinos, D.
JO - Cardiovascular and Hematological Agents in Medicinal Chemistry
PY - 2006
VL - 4
TODO - 4
SP - 361-367
PB - Bentham Science Publishers
SN - null
TODO - 10.2174/187152506784111454
TODO - acetylsalicylic acid;  alpha interferon;  alpha2b interferon;  anxiolytic agent;  beta interferon;  citalopram;  clopidogrel;  cytochrome P450;  dipeptidyl carboxypeptidase inhibitor;  escitalopram;  Fas ligand;  fluoxetine;  fluvoxamine;  imipramine;  interleukin 1;  interleukin 10;  interleukin 2;  interleukin 6;  maprotiline;  norfluoxetine;  nortriptyline;  omega 3 fatty acid;  paroxetine;  serotonin;  serotonin uptake inhibitor;  sertraline;  tricyclic antidepressant agent;  tumor necrosis factor;  unindexed drug;  von Willebrand factor, acute coronary syndrome;  bleeding;  body weight disorder;  bypass surgery;  cancer;  cardiotoxicity;  clinical trial;  comorbidity;  congestive heart failure;  coronary artery disease;  death;  depression;  drug half life;  drug mechanism;  drug metabolism;  evidence based medicine;  general condition deterioration;  heart arrhythmia;  heart failure;  heart infarction;  heart muscle conduction disturbance;  hepatitis C;  hormonal regulation;  hospitalization;  human;  immunostimulation;  major depression;  multiple sclerosis;  neuroendocrine system;  orthostatic hypotension;  outcome assessment;  pathophysiology;  pleiotropy;  prognosis;  QT prolongation;  review;  risk assessment;  serotonin syndrome;  thrombocyte function;  weight gain
TODO - Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. There is a significant body of evidence suggesting that the presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiologic mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the pleiotropic effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease. These bio-modulatory properties of SSRIs may be translated into improvement of patient clinical outcomes beyond their anti-depressant action. © 2006 Bentham Science Publishers Ltd.
ER -